Arcus Biosciences, Inc. 8-K

What Happened
Arcus Biosciences, Inc. (RCUS) filed an 8-K on March 23, 2026, announcing that Chief Operating Officer Jennifer Jarrett notified the company she will resign effective March 30, 2026. The filing states her resignation is not the result of any disagreement with the company’s operations, policies or practices.

Key Details

• Jennifer Jarrett’s resignation effective date: March 30, 2026.
• Separation agreement provides periodic advisory services through June 30, 2026.
• Company extended Ms. Jarrett’s post‑termination option exercise period for vested options to 12 months.
• Separation agreement includes a standard release of claims; the full agreement will be filed with the company’s next Form 10-Q.

Why It Matters
This is a material executive departure (COO) for Arcus; the company has arranged for transitional advisory support and extended option exercise rights, which can ease operational transition and affect Ms. Jarrett’s equity timing. Investors should note the company’s statement that the departure is not due to disagreements, and watch future filings (the upcoming 10‑Q) for the full separation agreement and any additional management changes or succession details.